New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Susvimo, a refillable eye implant, provides sustained efficacy in treating diabetic macular edema (DME) and diabetic retinopathy (DR) over two years. In the Pagoda study for DME, Susvimo demonstrated non-inferior visual acuity gains compared to monthly ranibizumab injections, with 95% of patients requiring no supplemental injections. In the Pavilion study for DR, Susvimo achieved superior improvements on the Diabetic Retinopathy Severity Scale compared to clinical observation, with 80% showing a two-step or greater improvement. Safety data for Susvimo was consistent with its known safety profile, with no new signals observed. The US FDA has accepted Roche's filing for Susvimo in DME and DR based on one-year results from Pagoda and Pavilion. Susvimo offers a unique therapeutic approach, providing continuous delivery of ranibizumab through a refillable implant. DME affects millions globally, leading to vision loss and reduced quality of life. DR causes damage to blood vessels in the retina, resulting in vision impairment and blindness. Roche has a broad ophthalmology pipeline focused on addressing leading causes of vision loss. Susvimo and Vabysmo are innovative ophthalmic treatments developed by Roche.